Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company operates within the biopharmaceutical and oncology industries, with a strategic emphasis on harnessing the immune system to generate targeted anti-tumor responses. Elicio’s core approach is centered on lymph node–targeted delivery of cancer vaccines and immunomodulatory agents designed to improve the magnitude and durability of immune activation.
The company’s primary business activities are driven by its proprietary AMP (Amphiphile) platform, which is designed to enhance the delivery of immunotherapies to lymph nodes. Its lead product candidate, ELI-002, targets KRAS-mutant solid tumors, including pancreatic and colorectal cancers, representing a significant unmet medical need. Elicio traces its origins to research founded by leading academic immunologists and evolved through corporate restructuring and rebranding to focus exclusively on oncology, culminating in its current public-company form following a reverse merger and Nasdaq listing.
Business Operations
Elicio’s operations are organized around a single reportable segment focused on oncology drug discovery and clinical development. Revenue generation is currently non-commercial, with activities funded primarily through equity financing and proceeds from public offerings, as the company does not yet have approved products. Research and development efforts are concentrated on advancing ELI-002 through clinical trials and expanding the application of the AMP platform to additional tumor-associated antigens.
Operationally, Elicio conducts clinical development in collaboration with contract research organizations and maintains strategic relationships with academic institutions and clinical trial sites. The company does not report material commercial partnerships or revenue-generating joint ventures as of its most recent public disclosures. Data inconclusive based on available public sources regarding any wholly owned operating subsidiaries beyond the parent entity.
Strategic Position & Investments
Elicio’s strategic direction is focused on establishing lymph node–targeted immunotherapy as a differentiated modality in cancer treatment, particularly in genetically defined patient populations. Growth initiatives center on clinical validation of ELI-002, progression into later-stage trials, and potential pipeline expansion leveraging the AMP platform. The company positions itself at the intersection of cancer vaccines and immuno-oncology, an area of sustained scientific and investor interest.
Investment activity has primarily consisted of internal R&D spending rather than external acquisitions. Elicio has not disclosed any material acquisitions of other companies or controlling investments in external portfolio companies. Emerging areas of focus include combination immunotherapy strategies and applications of its delivery technology across multiple solid tumor types, though specific future programs beyond current disclosures remain subject to clinical outcomes.
Geographic Footprint
Elicio Therapeutics is headquartered in Boston, Massachusetts, a major biotechnology hub in the United States. Its primary operations, including research management and corporate functions, are based in this region. Clinical trials are conducted across multiple sites, predominantly within North America, with some international participation depending on trial design and regulatory approvals.
While the company does not maintain significant physical operations outside the United States, its clinical development activities give it a functional presence in select international markets. As of the latest publicly available information, Elicio does not report material overseas manufacturing facilities or long-term foreign subsidiaries. Data inconclusive based on available public sources regarding permanent operational infrastructure outside the U.S.
Leadership & Governance
Elicio is led by an executive team with experience in biotechnology, oncology drug development, and public-company management. The leadership emphasizes disciplined clinical execution, translational science, and strategic capital allocation to advance its immunotherapy pipeline. The company is governed by a board of directors with backgrounds spanning life sciences, finance, and healthcare innovation.
Key executives include:
- Robert Connelly – President and Chief Executive Officer
- Thomas Shea – Chief Financial Officer
- Christina Coughlin, M.D., Ph.D. – Chief Medical Officer
- Seth Ettenberg, Ph.D. – Chief Scientific Officer
The company’s scientific roots are linked to its original founders from the academic immunology community, though day-to-day leadership is now overseen by the current executive management team. Leadership philosophy, as reflected in public filings and investor communications, centers on translating foundational immunology into clinically meaningful cancer therapies.